Condition: Hepatocellular Carcinoma · Sponsor: Seoul National University Hospital
The RESOLVE trial, an open-label, single-arm, multi-center study, aims to assess the efficacy and safety of ablative radioembolization using TheraSphere Yttrium-90 microspheres. This trial specifically targets patients diagnosed with hepatocellular carcinoma accompanied by localized portal vein tumor thrombosis (Vp1-Vp3) and who maintain good liver function.
This description comes directly from the study's public registry record.
Jin Woo Choi, MD, PhD · +82-220722584 · jwchoi.med@snu.ac.kr
Always discuss trial participation with your own doctor first.
| National Cancer Center | Ilsan, Gyeonggi-do, South Korea | Recruiting |
| Seoul National University Hospital | Seoul, Seoul, South Korea | Recruiting |
| Severance Hospital | Seoul, South Korea | Recruiting |
| Samsung Medical Center | Seoul, South Korea | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06166576